HOpe for contrast-induced acute kidney injury

Kidney International

Volumn 72, Issue 8, 2007, Pages 907-909

  Curtis, L M ^a   Agarwal, A ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEME OXYGENASE 1; PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CONTRAST INDUCED NEPHROPATHY; DRUG EFFECT; HOSPITAL PATIENT; KIDNEY; KIDNEY DISEASE; KIDNEY INJURY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 34948907908     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002530     Document Type: Note

References (29)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936.
2. Manske CL, Sprafka JM, Strony JT et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-620.
3. Sadeghi HM, Stone GW, Grines CL et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769-2775.
4. Nikolsky E, Mehran R, Turcot D et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004; 94: 300-305.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494.
6. Shusterman N, Strom BL, Murray TG et al. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med 1987; 83: 65-71.
7. Stacul F, Adam A, Becker CR et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98: 59K-77K.
8. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-2334.
9. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553-558.
10. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
11. Spargias K, Alexopoulos E, Kyrzopoulos S et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 2837-2842.
12. Kapoor A, Sinha N, Sharma RK et al. Use of dopamine in prevention of contrast induced acute renal failure: a randomised study. Int J Cardiol 1996; 53: 233-236.
13. Madyoon H, Croushore L, Weaver D et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001; 53: 341-345.
14. Allaqaband S, Tumuluri R, Malik AM et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57: 279-283.
15. Stone GW, McCullough PA, Tumlin JA et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291.
16. Tumlin J, Stacul F, Adam A et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006; 98: 14-20.
17. Applegate LA, Luscher P, Tyrrell RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res 1991; 51: 974-978.
18. Nath KA, Balla G, Vercellotti GM et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 1992; 90: 267-270.
19. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int 2006; 70: 432-443.
20. Goodman AI, Olszanecki R, Yang LM et al. Heme oxygenase-1 protects against radiocontrast-induced acute kidney injury by regulating anti-apoptotic proteins. Kidney Int 2007; 72: 945-9530.
21. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 2007; 18: 414-420.
22. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288: F778-F784.
23. Nakao A, Neto JS, Kanno S et al. Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant 2005; 5: 282-291.
24. Tayem Y, Johnson TR, Mann BE et al. Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. Am J Physiol Renal Physiol 2006; 290: F789-F794.
25. Mori K, Lee HT, Rapoport D et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115: 610-621.
26. Lam CW, Getting SJ, Perretti M. In vitro and in vivo induction of heme oxygenase 1 in mouse macrophages following melanocortin receptor activation. J Immunol 2005; 174: 2297-2304.
27. Calo LA, Davis PA, Piccoli A et al. A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story? Nephron Physiol 2006; 103: 107-111.
28. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 2002; 8: 240-246.
29. Lee TS, Chang CC, Zhu Y et al. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004; 110: 1296-1302.